DOCSLIB.ORG

ICH Guideline Q3D (R1) on Elemental Impurities Step 5

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ICH Guideline Q3D (R1) on Elemental Impurities Step 5 28 March 2019 EMA/CHMP/ICH/353369/2013 Committee for Human Medicinal Products ICH guideline Q3D (R1) on elemental impurities Step 5 Transmission to CHMP 26 April 2018 Adoption by CHMP 26 April 2018 Release for public consultation 26 April 2018 End of consultation on the Cadmium Inhalation PDE (deadline for 26 July 2018 comments) Final adoption by CHMP 28 March 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE GUIDELINE FOR ELEMENTAL IMPURITIES Q3D(R1) Final version Adopted on 22 March 2019 This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of ICH regions. ICH Q3D(R1) Guideline Q3D(R1) Document History Code History Date Q3D(R1) Revision of the Cadmium Inhalation PDE 22 March 2019 Adoption by the Regulatory Members of the ICH Assembly under Step 4. Q3D(R1) Revision of the Cadmium Inhalation PDE 18 May 2018 Endorsement by the Members of the ICH Assembly under Step 2 and release for public consultation. Corrigendum to correct: the modifying factor in the 16 December text of the safety assessment for Selenium 2014 (changed to 2 instead of 10 consistent with Section Q3D 3.1); and two references for consistency in the safety assessments for Barium (deleted reference) and Vanadium (revised reference). Approval by the Steering Committee under Step 4 12 November Q3D and recommendation for adoption to the ICH 2014 regulatory bodies. 30 September Q3D Addition of line numbers to facilitate the provision of comments by stakeholders. 2013 Post sign-off minor editorial corrections including: 26 July removal of references to Appendix 5 (pgs i & 13); 2013 deletion of redundant text (pg 4); change of Option 2 to Option 2a (pg 10); insertion of omitted text Q3D under Safety Limiting Toxicity (pg 35); removal of duplicated redundant text (pg 41); replacing references to “metals” in text and “metal” in Table A.4.7 title with “elementals” and “elements” (pg 73); and deletion of header Table A.4.10 (pg 75). Post sign-off corrigendum in: 14 June Table 4.1 W and Al were removed from the list of 2013 Q3D included elemental impurities in Class 2B and 3 respectively. Table A.2.1 the Class for Ni was changed to read 3 instead of 2. Approval by the Steering Committee under Step 2b 6 June Q3D and release for public consultation. 2013 Approval by the Steering Committee under Step 6 June 2013 Q3D 2a. 2 ICH Q3D(R1) Guideline Legal notice: This document is protected by copyright and may, with the exception of the ICH logo, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the document is acknowledged at all times. In case of any adaption, modification or translation of the document, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original document. Any impression that the adaption, modification or translation of the original document is endorsed or sponsored by the ICH must be avoided. The document is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original document be liable for any claim, damages or other liability arising from the use of the document. The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder. 3 ICH HARMONISED GUIDELINE GUIDELINE FOR ELEMENTAL IMPURITIES Q3D(R1) ICH Consensus Guideline TABLE OF CONTENTS 1. INTRODUCTION .................................................................................................................. 2 2. SCOPE ..................................................................................................................................... 2 3. SAFETY ASSESSMENT OF POTENTIAL ELEMENTAL IMPURITIES ...................... 3 3.1 Principles of the Safety Assessment of Elemental Impurities for Oral, Parenteral and Inhalation Routes of Administration ......................................................................................... 3 3.2 Other Routes of Administration ................................................................................................ 4 3.3 Justification for Elemental Impurity Levels Higher than an Established PDE ......................... 4 3.4 Parenteral Products ................................................................................................................... 5 4. ELEMENT CLASSIFICATION ........................................................................................... 5 5. RISK ASSESSMENT AND CONTROL OF ELEMENTAL IMPURITIES ..................... 6 5.1 General Principles .................................................................................................................... 7 5.2 Potential Sources of Elemental Impurities ............................................................................... 7 5.3 Identification of Potential Elemental Impurities....................................................................... 8 5.4 Recommendations for Elements to be Considered in the Risk Assessment ............................. 9 5.5 Evaluation ............................................................................................................................... 10 5.6 Summary of Risk Assessment Process ................................................................................... 11 5.7 Special Considerations for Biotechnologically-Derived Products ......................................... 11 6. CONTROL OF ELEMENTAL IMPURITIES ............................................................................... 12 7. CONVERTING BETWEEN PDES AND CONCENTRATION LIMITS.......................................... 12 8. SPECIATION AND OTHER CONSIDERATIONS .......................................................... 14 9. ANALYTICAL PROCEDURES ......................................................................................... 15 10. LIFECYCLE MANAGEMENT .......................................................................................... 15 GLOSSARY ..................................................................................................................................... 16 REFERENCES ................................................................................................................................ 21 APPENDIX 1: METHOD FOR ESTABLISHING EXPOSURE LIMITS ................................. 22 APPENDIX 2: ESTABLISHED PDES FOR ELEMENTAL IMPURITIES .............................. 25 APPENDIX 3: INDIVIDUAL SAFETY ASSESSMENTS ........................................................... 27 APPENDIX 4: ILLUSTRATIVE EXAMPLES ............................................................................ 76 1 ICH Q3D(R1) Guideline GUIDELINE FOR ELEMENTAL IMPURITIES Q3D(R1) 1. INTRODUCTION Elemental impurities in drug products may arise from several sources; they may be residual catalysts that were added intentionally in synthesis or may be present as impurities (e.g., through interactions with processing equipment or container/closure systems or by being present in components of the drug product). Because elemental impurities do not provide any therapeutic benefit to the patient, their levels in the drug product should be controlled within acceptable limits. There are three parts of this guideline: the evaluation of the toxicity data for potential elemental impurities; the establishment of a Permitted Daily Exposure (PDE) for each element of toxicological concern; and application of a risk-based approach to control elemental impurities in drug products. An applicant is not expected to tighten the limits based on process capability, provided that the elemental impurities in drug products do not exceed the PDEs. The PDEs established in this guideline are considered to be protective of public health for all patient populations. In some cases, lower levels of elemental impurities may be warranted when levels below toxicity thresholds have been shown to have an impact on other quality attributes of the drug product (e.g., element catalyzed degradation of drug substances). In addition, for elements with high PDEs, other limits may have to be considered from a pharmaceutical quality perspective and other guidelines should be consulted (e.g., ICH Q3A). This guideline presents a process to assess and control elemental impurities in the drug product using the principles of risk management as described in ICH Q9. This process provides a platform for developing a risk-based control strategy to limit elemental impurities in the drug product. 2. SCOPE The guideline applies to new finished drug products (as defined in ICH Q6A and Q6B) and new drug products containing existing drug substances. The drug products containing purified proteins and polypeptides (including proteins and polypeptides produced
Load more

Recommended publications
  • Food Additives Safety and Maximum Use Level
    5/10/2017 FOOD ADDITIVES SAFETY & MAXIMUM USE LEVEL Nuri Andarwulan SEAFAST Center, IPB (Southeast Asian Food & Agr. Sci & Tech Center) Departemen Ilmu dan Teknologi Pangan, IPB [email protected] Outline Food additives Chemicals HOW are food additives regulated? Maximum use level of food additive [email protected] 1 5/10/2017 Food Additive is a substance (intentionally) added to food to alter the properties and/or the appearance of the food [email protected] As described by Paracelsus nearly 500 years ago, “All substances are poisons; there is none which is not a poison. The right dose differentiates a poison and a remedy”. This means that any chemical substance is likely to produce some form(s) of harmful effect, if taken in sufficient quantity. More addition of a chemical in food does not itself make food unsafe, but the quantity used in food, quantity of that food consumed and bodyweight will decide the safety. [email protected] 2 5/10/2017 The Codex definition of hazard is “a biological, chemical or physical agent with the potential to cause an adverse health effect”. The likelihood or risk of that hazard actually occurring in humans is dependent upon the quantity of chemical encountered or taken into the body, i.e. the exposure. [email protected] WHY do we need to regulate food additives? These chemicals may be harmful to your health (if consumed above the safety margin level) Benford, D. 2000, ILSI Europe [email protected] 3 5/10/2017 Food Additive (Codex Stan 192-1995) • Any substance not normally consumed as a food by itself and not normally used as a typical ingredient of the food, whether or not it has nutritive value, the intentional addition of which to food for a technological (including organoleptic) purpose in the manufacture, processing, preparation, treatment, packing, packaging and transport.
    [Show full text]
  • Elemental Motes by Charles Choi Illustration by Rob Alexamder Little Fires up the Imagination More Than a Vision of the Well
    Fantastic Terrain: Elemental Motes By Charles Choi illustration by Rob Alexamder Little fires up the imagination more than a vision of the well. The awe-inspiring heights that motes often soar at carry impossible, such as an island defying gravity by floating miles the promise of death-defying acts of derring-do that can stick high up in the air. This might be why castles in the sky are so with players for years. Although the constant risk of a poten- common in fantasy, from the ethereal cloud kingdoms seen tially lethal fall underlies the greatest strength of motes as a in fairy tales such as Jack and the Beanstalk to the ominous storytelling tool—spine-tingling suspense—unfortunately, it is flying citadels of Krynn in Dragonlance. also their greatest weakness. One wrong step on the part of either Dungeon Master or player, and a player character or Islands in the sky made their debut in 4th Edition as valuable nonplayer character can inadvertently go hurtling earthmotes in the updated Forgotten Realms® setting, and into the brink. However, such challenges can be overcome now they can be unforgettable elements in your campaign as easily with a little forethought. TM & © 2009 Wizards of the Coast LLC All rights reserved. March 2010 | Dungeon 176 76 Fantastic Terrain: Elemental Motes Motes in On the flipside, in settings where air travel is common, such as the Eberron® setting, motes Facts abouT Motes Your CaMpaign could become common ports of call. Such mote- Motes are often born from breaches between the ports can brim with adventure and serve as home mortal world and the Elemental Chaos, when matter In a game that includes monster-infested dungeons, to all kinds of intrigue.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 4,496,778 Myers Et Al
    United States Patent (19) 11 Patent Number: 4,496,778 Myers et al. (45) Date of Patent: Jan. 29, 1985 (54) PROCESS FOR THE HYDROXYLATION OF 56 References Cited OLEFINS USING MOLECULAR OXYGEN, U.S. PATENT DOCUMENTS ANOSMIUM CONTAINING CATALYST, A COPPER CO-CATALYST, AND AN 2,773, 101 12/1956 Smith et al. ......................... 568/860 AROMATIC AMINE BASED PROMOTER 3,317,592 5/1967 Maclean et al. ... 568/860 3,337,635 8/1967 Norton et al. ....... 568/860 75 Inventors: Richard S. Myers, Fairlawn; Robert 4,390,739 6/1983 Michaelson et al. .... ..., 568/860 C. Michaelson, Waldwick; Richard FOREIGN PATENT DOCUMENTS G. Austin, Ridgewood, all of N.J. 32522 8/1974 Japan ................................... 568/860 73) Assignee: Exxon Research & Engineering Co., Primary Examiner-J. E. Evans Florham Park, N.J. Attorney, Agent, or Firm-Robert A. Maggio 21 Appl. No.: 538,190 57 ABSTRACT A process directed to the hydroxylation of olefins by 22 Filed: Oct. 3, 1983 reacting said olefins in the presence of oxygen, water, and a catalyst composition comprising (i) a catalytically 51 Int. Cl. ...................... C07C 29/04; CO7C 31/18; active osmium containing compound, (ii) a Co-catalyst C07C 31/22; CO7C 31/42 I comprising a copper containing compound such as 52 U.S.C. ................................. 568/860; 260/.397.2; CuBr2, and (iii) a Co-catalyst II capable of increasing 560/186; 562/587; 568/811; 568/821; 568/833; the rate and/or selectivity of the hydroxylation reac 568/838; 568/847 tion, such as pyridine is disclosed. 58 Field of Search ..............
    [Show full text]
  • Meike Weijtmans S4235797 BA Thesis English Language and Culture Supervisor: Dr
    Weijtmans, s4235797/1 Meike Weijtmans s4235797 BA Thesis English Language and Culture Supervisor: dr. Chris Cusack Examiner: dr. L.S. Chardonnens August 15, 2018 The Celtic Image in Contemporary Adaptations of the Arthurian Legend M.A.S. Weijtmans BA Thesis August 15, 2018 Weijtmans, s4235797/2 ENGELSE TAAL EN CULTUUR Teacher who will receive this document: dr. Chris Cusack, dr. L.S. Chardonnens Title of document: The Celtic Image in Contemporary Adaptations of the Arthurian Legend Name of course: BA Thesis Date of submission: August 15, 2018 The work submitted here is the sole responsibility of the undersigned, who has neither committed plagiarism nor colluded in its production. Signed Name of student: Meike Weijtmans Student number: s4235797 Weijtmans, s4235797/3 Abstract Celtic culture has always been a source of interest in contemporary popular culture, as it has been in the past; Greek and Roman writers painted the Celts as barbaric and uncivilised peoples, but were impressed with their religion and mythology. The Celtic revival period gave birth to the paradox that still defines the Celtic image to this day, namely that the rurality, simplicity and spirituality of the Celts was to be admired, but that they were uncivilised, irrational and wild at the same time. Recent debates surround the concepts of “Celt”, “Celticity” and “Celtic” are also discussed in this thesis. The first part of this thesis focuses on Celtic history and culture, as well as the complexities surrounding the terminology and the construction of the Celtic image over the centuries. This main body of the thesis analyses the way Celtic elements in contemporary adaptations of the Arthurian narrative form the modern Celtic image.
    [Show full text]
  • Cellular Uptake and Toxicological Effects of Differently Sized Zinc Oxide Nanoparticles in Intestinal Cells †
    toxics Article Cellular Uptake and Toxicological Effects of Differently Sized Zinc Oxide Nanoparticles in Intestinal Cells † Anna Mittag 1,* , Christian Hoera 2, Alexander Kämpfe 2 , Martin Westermann 3, Jochen Kuckelkorn 4, Thomas Schneider 1 and Michael Glei 1 1 Department of Nutritional Toxicology, Institute of Nutritional Sciences, Friedrich Schiller University Jena, Dornburger Straße 24, 07743 Jena, Germany; [email protected] (T.S.); [email protected] (M.G.) 2 German Environment Agency, Swimming Pool Water, Chemical Analytics, Heinrich-Heine-Straße 12, 08645 Bad Elster, Germany; [email protected] (C.H.); [email protected] (A.K.) 3 Electron Microscopy Centre, Friedrich Schiller University Jena, Ziegelmühlenweg 1, 07743 Jena, Germany; [email protected] 4 German Environment Agency, Toxicology of Drinking Water and Swimming Pool Water, Heinrich-Heine-Straße 12, 08645 Bad Elster, Germany; [email protected] * Correspondence: [email protected] † In respectful memory of Dr. Tamara Grummt. Abstract: Due to their beneficial properties, the use of zinc oxide nanoparticles (ZnO NP) is constantly increasing, especially in consumer-related areas, such as food packaging and food additives, which is leading to an increased oral uptake of ZnO NP. Consequently, the aim of our study was to investigate the cellular uptake of two differently sized ZnO NP (<50 nm and <100 nm; 12–1229 µmol/L) using two human intestinal cell lines (Caco-2 and LT97) and to examine the possible resulting toxic effects. ZnO NP (<50 nm and <100 nm) were internalized by both cell lines and led to intracellular changes. Citation: Mittag, A.; Hoera, C.; Kämpfe, A.; Westermann, M.; Both ZnO NP caused time- and dose-dependent cytotoxic effects, especially at concentrations of Kuckelkorn, J.; Schneider, T.; Glei, M.
    [Show full text]
  • Ruthenium Tetroxide (Ruo4) Oxidation of N-Alkyllactams Proceeded Regioselectively Depend- Ing on the Size of Lactam Ring, Except for the Seven-Membered Ring
    No. 1 357 Chem. Pharm. Bull. 35(1) 357-363 (1987) Ruthenium Tetroxide Oxidation of N-Alkyllactams SHIGEYUKIYOSHIFUJI,* YUKIMI ARAKAWA, and YOSHIHIRONITTA Schoolof Pharmacy,Hokuriku University,Kanagawa-machi, Kanazawa920-11, Japan (ReceivedJuly 31, 1986) Ruthenium tetroxide (RuO4) oxidation of N-alkyllactams proceeded regioselectively depend- ing on the size of lactam ring, except for the seven-membered ring. Four- and eight-membered N- methyl- and N-ethyllactams were oxidized at the exocyclic ƒ¿-carbon adjacent to nitrogen to produce the N-acyllactams and NH-lactams, while five- and six-membered lactams underwent endocyclic oxidation to yield the cyclic imides. Oxidation of seven-membered lactams yielded a mixture of products arising from both exocyclic and endocyclic oxidations. These regioselectivities were confirmed in the oxidation of substrates having a tertiary carbon at the oxidation position. Keywords•\oxidation; ruthenium tetroxide oxidation; regioselective oxidation; hydroxyl- ation; imide synthesis; N-alkyllactam; N-acyllactam; imide; ruthenium tetroxide; two-phase method Ruthenium tetroxide (RuO4) is a good reagent for the conversion of N-acylated cyclic amines to the corresponding lactams,1) by oxidation of one of two carbons adjacent to nitrogen. As a common feature of the RuO4 oxidation in this conversion (la to 2 in Chart 1) and in the transformation of cyclic ethers into the corresponding lactones,2) it has been considered that RuO4 predominantly oxidizes a secondary carbon rather than a tertiary one. However, as reported previously,3) we obtained an opposite result in the RuO4 oxidation of some 1-azabicycloalkan-2-ones, such as quinolizidin-4-one (1b), which gave the hydroxylated products, such as 3, resulting from the oxidation of the tertiary carbon.
    [Show full text]
  • 61Ni Synchrotron-Radiation-Based Mössbauer Absorption
    Hyperfine Interact (2018) 239:11 https://doi.org/10.1007/s10751-018-1488-0 61Ni synchrotron-radiation-based Mossbauer¨ absorption spectroscopy of Ni nanoparticle composites Ryo Masuda1 · Hirokazu Kobayashi2,3 · Yoshimasa Aoyama2 · Makina Saito1 · Shinji Kitao1 · Hiroki Ishibashi1 · Shuichi Hosokawa1 · Takaya Mitsui4 · Yoshitaka Yoda5 · Hiroshi Kitagawa2 · Makoto Seto1,4 © Springer International Publishing AG, part of Springer Nature 2018 Abstract We obtained energy-domain 61Ni synchrotron-radiation-based Mossbauer¨ absorption spectra of three materials that relate to nanoparticles: Ni2(C8O6H2) metal- organic frameworks (MOFs), Ni nanoparticles synthesized by complete heat decomposition of the MOFs, and the composites of Ni nanoparticles and the MOFs synthesized by par- tial decomposition of the MOFs. The 61Ni abundance of all the samples was not enriched but we were successfully able to obtain their spectra in 1 day or less, by using a highly efficient measurement system where the internal conversion electrons from energy standard 61 Ni86V14 foil were detected. Although both nanoparticle constituent and MOF constituent in the composites included Ni atoms, the Mossbauer¨ parameters of the Ni nanoparticle con- stituent could be evaluated; the magnetic hyperfine field of the Ni nanoparticle constituent in the composites was different from that of the Ni nanoparticles obtained by the complete heat decomposition. This difference implied that the 3d and/or 4s electron configuration of the nanoparticle constituent were affected by the MOF constituent
    [Show full text]
  • The Two Faces of Titanium Dioxide Nanoparticles Bio-Camouflage in 3D
    www.nature.com/scientificreports OPEN The two faces of titanium dioxide nanoparticles bio-camoufage in 3D bone spheroids Received: 23 October 2018 W. Souza1,2,3, S. G. Piperni3,4, P. Laviola1,3,5, A. L. Rossi4, Maria Isabel D. Rossi6, Accepted: 11 June 2019 Bráulio S. Archanjo7, P. E. Leite 1,2,8, M. H. Fernandes9,12, L. A. Rocha3,10, J. M. Granjeiro1,2,3,11 Published: xx xx xxxx & A. R. Ribeiro 2,3,5 Titanium (Ti) and its alloys are widely used in dental implants and hip-prostheses due to their excellent biocompatibility. Growing evidence support that surface degradation due to corrosion and wear processes, contribute to implant failure, since the release of metallic ions and wear particles generate local tissue reactions (peri-implant infammatory reactions). The generated ions and wear debris (particles at the micron and nanoscale) stay, in a frst moment, at the interface implant-bone. However, depending on their size, they can enter blood circulation possibly contributing to systemic reactions and toxicities. Most of the nanotoxicological studies with titanium dioxide nanoparticles (TiO2 NPs) use conventional two-dimensional cell culture monolayers to explore macrophage and monocyte activation, where limited information regarding bone cells is available. Recently three- dimensional models have been gaining prominence since they present a greater anatomical and physiological relevance. Taking this into consideration, in this work we developed a human osteoblast- like spheroid model, which closely mimics bone cell-cell interactions, providing a more realistic scenario for nanotoxicological studies. The treatment of spheroids with diferent concentrations of TiO2 NPs during 72 h did not change their viability signifcantly.
    [Show full text]
  • Lithium Carbonate; [2] Lithium Chloride; [3] Lithium Hydroxide
    CLH REPORT FOR LITHIUM SALTS CLH report Proposal for Harmonised Classification and Labelling Based on Regulation (EC) No 1272/2008 (CLP Regulation), Annex VI, Part 2 International Chemical Identification: [1] Lithium carbonate; [2] lithium chloride; [3] lithium hydroxide EC Number: [1] 209-062-5; [2] 231-212-3; [3] 215-183-4 CAS Number: [1] 554-13-2; [2] 7447-41-8; [3] 1310-65-2 Index Number: - Contact details for dossier submitter: ANSES (on behalf of the French MSCA) 14 rue Pierre Marie Curie F-94701 Maisons-Alfort Cedex [email protected] Version number: 02 Date: June 2020 CLH REPORT FOR LITHIUM SALTS CONTENTS 1 IDENTITY OF THE SUBSTANCE........................................................................................................................1 1.1 NAME AND OTHER IDENTIFIERS OF THE SUBSTANCES .............................................................................................1 1.1.1 Lithium carbonate ........................................................................................................................................1 1.1.2 Lithium chloride ...........................................................................................................................................2 1.1.3 Lithium hydroxide.........................................................................................................................................3 1.2 COMPOSITION OF THE SUBSTANCE..........................................................................................................................3
    [Show full text]
  • Exposures Associated with Clandestine Methamphetamine Drug Laboratories in Australia
    Rev Environ Health 2016; 31(3): 329–352 Jackie Wright*, John Edwards and Stewart Walker Exposures associated with clandestine methamphetamine drug laboratories in Australia DOI 10.1515/reveh-2016-0017 Received April 20, 2016; accepted June 7, 2016; previously published Introduction online July 18, 2016 Illicit drugs such as amphetamine-type stimulants (ATS) Abstract: The clandestine manufacture of methamphet- (1) are manufactured in Australia within clandestine amine in residential homes may represent significant laboratories that range from crude, makeshift operations hazards and exposures not only to those involved in the using simple processes to sophisticated operations. These manufacture of the drugs but also to others living in the laboratories use a range of chemical precursors to manu- home (including children), neighbours and first respond- facture or “cook” ATS that include methylamphetamine, ers to the premises. These hazards are associated with more commonly referred to as methamphetamine (“ice”) the nature and improper storage and use of precursor and 3,4-methylenedioxymethamphetamine (MDMA or chemicals, intermediate chemicals and wastes, gases and “ecstasy”). In Australia the primary ATS manufactured methamphetamine residues generated during manufac- in clandestine drug laboratories is methamphetamine ture and the drugs themselves. Many of these compounds (2), which is the primary focus of this review. Clandes- are persistent and result in exposures inside a home not tine laboratories are commonly located within residential only during manufacture but after the laboratory has been homes, units, hotel rooms, backyard sheds and cars, with seized or removed. Hence new occupants of buildings for- increasing numbers detected in Australia each year (744 merly used to manufacture methamphetamine may be laboratories detected in 2013–2014) (2).
    [Show full text]
  • And Tipt-Based High-Temperature Shape Memory Alloys: a Review on Recent Advances
    metals Review TiPd- and TiPt-Based High-Temperature Shape Memory Alloys: A Review on Recent Advances Yoko Yamabe-Mitarai 1,2 1 Department of Advanced Materials Science, Graduate School of Frontier Sciences, The University of Tokyo, 5-1-5 Kashiwanoha, Kashiwa-shi, Chiba 277-8561, Japan; [email protected] 2 National Institute for Materials Science, 1-2-1 Sengen, Tsukuba, Ibaraki 305-0047, Japan Received: 30 September 2020; Accepted: 12 November 2020; Published: 18 November 2020 Abstract: In this paper high-temperature shape memory alloys based on TiPd and TiPt are reviewed. The effect of the alloying elements in ternary TiPd and TiPt alloys on phase transformation and strain recovery is also discussed. Generally, the addition of alloying elements decreases the martensitic transformation temperature and improves the strength of the martensite and austenite phases. Additionally, it also decreases irrecoverable strain, but without perfect recovery due to plastic deformation. With the aim to improve the strength of high-temperature shape memory alloys, multi-component alloys, including medium- and high-entropy alloys, have been investigated and proposed as new structural materials. Notably, it was discovered that the martensitic transformation temperature could be controlled through a combination of the constituent elements and alloys with high austenite finish temperatures above 500 ◦C. The irrecoverable strain decreased in the multi-component alloys compared with the ternary alloys. The repeated thermal cyclic test was effective toward obtaining perfect strain recoveries in multi-component alloys, which could be good candidates for high-temperature shape memory alloys. Keywords: high-temperature shape memory alloys; titanium palladium; titanium platinum; multi-component alloys; medium-entropy alloys; high-entropy alloys 1.
    [Show full text]
  • Ec:Rbfc/2010/3
    EC:RBFC/2010/3 Food and Agriculture Organization of the United Nations JOINT FAO/WHO EXPERT CONSULTATION ON THE RISKS AND BENEFITS OF FISH CONSUMPTION Rome, Italy, 25 - 29 January 2010 HEALTH RISKS ASSOCIATED WITH FISH CONSUMPTION FOCUS ON METHYLMERCURY, DIOXINS AND DIOXIN-LIKE PCBS Lucio G. Costa Professor, Department of Occupational and Health Sciences University of Washington, Seattle, USA & Vittorio Fattori Nutrition and Consumer Protection Division, FAO, Rome, Italy 2 EC:RBFC/2010/3 TABLE OF CONTENTS 1 INTRODUCTION ......................................................................................... 4 1.1 Objective and Scope of the paper ................................................................ 4 2 CONTAMINANTS IN FISH ........................................................................... 4 3 INTERNATIONAL ADVISORIES ................................................................... 6 3.1 Mercury ....................................................................................................... 6 4 MERCURY ................................................................................................... 8 4.1 Mercury in the environment ....................................................................... 8 4.1.1 The environmental cycle of mercury ............................................................................ 8 4.1.2 Main sources of mercury release into environment ..................................................... 9 4.1.3 Main food sources .......................................................................................................
    [Show full text]